GENELUX CORP (GNLX) Stock Price, Quote, News and Overview
NASDAQ:GNLX - Nasdaq - US36870H1032 - Common Stock - Currency: USD
GNLX Quote, Performance and Key Statistics
4.81
-0.01 (-0.21%)
The current stock price of GNLX is 4.81 USD. In the past month the price increased by 43.15%. In the past year, price decreased by -27.89%.
GNLX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About GNLX
Company Profile
Genelux Corp. manufactures and markets drugs and virus strains solutions. The company is headquartered in Westlake Village, California and currently employs 23 full-time employees. The company went IPO on 2023-01-26. The firm is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
Company Info
GENELUX CORP
2625 Townsgate Road, Suite 230
Westlake Village CALIFORNIA US
Employees: 24
Company Website: https://genelux.com/
Investor Relations: https://www.genelux.com/investors/
Phone: 18052679889
GENELUX CORP / GNLX FAQ
What is the stock price of GENELUX CORP today?
The current stock price of GNLX is 4.81 USD. The price decreased by -0.21% in the last trading session.
What is the ticker symbol for GENELUX CORP stock?
The exchange symbol of GENELUX CORP is GNLX and it is listed on the Nasdaq exchange.
On which exchange is GNLX stock listed?
GNLX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for GENELUX CORP stock?
10 analysts have analysed GNLX and the average price target is 18.77 USD. This implies a price increase of 290.19% is expected in the next year compared to the current price of 4.81. Check the GENELUX CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GENELUX CORP worth?
GENELUX CORP (GNLX) has a market capitalization of 166.14M USD. This makes GNLX a Micro Cap stock.
How many employees does GENELUX CORP have?
GENELUX CORP (GNLX) currently has 24 employees.
What are the support and resistance levels for GENELUX CORP (GNLX) stock?
GENELUX CORP (GNLX) has a support level at 4.8 and a resistance level at 5.35. Check the full technical report for a detailed analysis of GNLX support and resistance levels.
Is GENELUX CORP (GNLX) expected to grow?
The Revenue of GENELUX CORP (GNLX) is expected to decline by -97.75% in the next year. Check the estimates tab for more information on the GNLX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy GENELUX CORP (GNLX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GNLX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GNLX, evaluating the profitability, health, valuation and growth aspects
- GENELUX CORP (GNLX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GENELUX CORP (GNLX) Sales and EPS estimates to see what analysts future expectations are.
- GENELUX CORP (GNLX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GENELUX CORP (GNLX) Insider and Institutional Ownership to learn about the owners and their transactions.
- GENELUX CORP (GNLX) Stock Chart to make your own analysis
- GENELUX CORP (GNLX) Latest news and press-releases to stay up to date.
Does GENELUX CORP (GNLX) stock pay dividends?
GNLX does not pay a dividend.
What is the Price/Earnings (PE) ratio of GENELUX CORP (GNLX)?
GENELUX CORP (GNLX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.95).
What is the Short Interest ratio of GENELUX CORP (GNLX) stock?
The outstanding short interest for GENELUX CORP (GNLX) is 6.48% of its float. Check the ownership tab for more information on the GNLX short interest.
GNLX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to GNLX. When comparing the yearly performance of all stocks, GNLX is one of the better performing stocks in the market, outperforming 90.29% of all stocks.
GNLX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GNLX. GNLX has a great financial health rating, but its profitability evaluates not so good.
GNLX Financial Highlights
Over the last trailing twelve months GNLX reported a non-GAAP Earnings per Share(EPS) of -0.95. The EPS decreased by -451.58% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -58.74% | ||
| ROE | -70.45% | ||
| Debt/Equity | 0 |
GNLX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to GNLX. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 25.19% and a revenue growth -97.75% for GNLX